In this issue:
ULTIMATE: 5-year follow-up of ublituximab in MS
Relapse rates with a switch to oral/infusion vs. injectable DMT in paediatric MS
Brain volume loss & disability with 16 different DMTs
Diagnostic/prognostic utility of the KFLC index
The KFLC index to distinguish MS from MOGAD/NMOSD
Lipoic acid in progressive MS
4 phenotypes of disability progression in MS
Burden of functional neurologic symptoms in MS
Assisted reproductive technology & relapse in women with RRMS
Progression with high BMI in early-life/adulthood in relapsing-onset MS
Please login below to download this issue (PDF)